Back to Stocks

VIVOS

VIVOS INC
2 filings tracked
healthcarebiotechnologyMICRO (<$300M)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Vivos Inc. is demonstrating a powerful pivot toward commercial viability, anchored by an explosive 1,200% year-over-year increase in administered IsoPet therapies.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the narrative of growth, Vivos remains in a precarious financial position, characterized by a widening net loss of $1.18 million for the first quarter of 2026.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every VIVOS filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The latest filing reveals a company at a binary crossroads, where the success of the veterinary division is being used to bridge the gap toward a high-stakes human medical breakthrough. While the 1,200% growth in animal therapies provides a proof-of-concept for the technology's safety and efficacy, it is currently insufficient to offset the heavy burn rate associated with FDA regulatory pursuits. The shift toward internal manufacturing and the establishment of the Indian LLP are necessary steps to reduce risk, but they require capital that the company is currently sourcing through aggressive equity issuance. Ultimately, the investment thesis rests on the outcome of the April 2026 IDE resubmission and the ability of the animal division to reach breakeven. If Vivos can secure FDA clearance and stabilize its cash flow, it could transform into a diversified oncology leader. However, the auditor's explicit 'going concern' warning serves as a stark reminder that without immediate regulatory success or further financing, the company's operational runway is dangerously short.

Selected Quarter

Core Takeaway

Vivos is proving its technology works in animals, but it remains a speculative bet on human FDA approval and continuous capital raises.

Investor Lens

Investors must weigh the high-growth potential of the veterinary division against the extreme dilution risk and binary regulatory outcome of the human therapy.

Watch Next

The outcome of the RadioGel IDE resubmission targeted for April 2026.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)-0.20Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bearishMay 14

Net loss widened to $1.18M from $835K year-over-year.

earnings miss
70%
bearishMay 14

Company continues to operate with a gross loss on its primary product line.

margin compression
60%
bullishMay 14

Raised $2.2M through Regulation A+ offerings to extend operational runway.

capital raise
50%
neutralMay 14

Preparing for critical IDE resubmission following previous FDA rejection.

regulatory action
80%
bearishMay 14

Net loss widened to $1.18M from $835K year-over-year.

earnings miss
70%
bearishMay 14

Company continues to operate with a gross loss on its primary product line.

margin compression
60%
bullishMay 14

Raised $2.2M through Regulation A+ offerings to extend operational runway.

capital raise
50%
neutralMay 14

Preparing for critical IDE resubmission following previous FDA rejection.

regulatory action
80%

Filing History

10-QMay 14, 2026
Expand Sequence

The latest filing reveals a company at a binary crossroads, where the success of the veterinary division is being used to bridge the gap toward a high-stakes human medical breakthrough. While the 1,200% growth in animal therapies provides a proof-of-concept for the technology's safety and efficacy, it is currently insufficient to offset the heavy burn rate associated with FDA regulatory pursuits. The shift toward internal manufacturing and the establishment of the Indian LLP are necessary steps to reduce risk, but they require capital that the company is currently sourcing through aggressive equity issuance. Ultimately, the investment thesis rests on the outcome of the April 2026 IDE resubmission and the ability of the animal division to reach breakeven. If Vivos can secure FDA clearance and stabilize its cash flow, it could transform into a diversified oncology leader. However, the auditor's explicit 'going concern' warning serves as a stark reminder that without immediate regulatory success or further financing, the company's operational runway is dangerously short.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.